Developer docs
API playgroundTry for free, no card

Search company profiles

Phoenix Tissue Repair

Full company profile

uuid003ahkr

Namestring
Phoenix Tissue Repair
Legal namestring
BridgeBio Pharma, Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Phoenix Tissue Repair is a private, early-stage biotechnology company founded in 2017 and headquartered in Boston, Massachusetts. According to its firmographic profile, the company is focused on advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare inherited skin disorder characterized by skin fragility and chronic blistering. The company operates with a small team of 1-10 employees, consistent with a research-stage biotech organization.

The bulk of the source content provided alongside this analysis pertains to BridgeBio Pharma, Inc., a separate late-stage pharmaceutical company with three FDA-approved products (Attruby/acoramidis and NULIBRY/fosdenopterin) and an investigational pipeline targeting multiple rare genetic diseases including ATTRv amyloidosis, LGMD2I/R9, ADH1, achondroplasia, hypochondroplasia, and Canavan disease. No product-level, financial, leadership, partnership, or strategic-move information specific to Phoenix Tissue Repair is disclosed in the input data beyond the firmographic profile. The relationship between Phoenix Tissue Repair and BridgeBio is not explicitly stated, and no underlying technology platform, business model, pricing, or revenue mechanics for Phoenix Tissue Repair can be characterized from the provided evidence.

Short descriptiontext

Phoenix Tissue Repair is a private, early-stage Boston-based biotechnology company founded in 2017 that is developing a novel treatment for Dystrophic Epidermolysis Bullosa, a rare inherited skin disorder.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, epidermolysis bullosa treatment, biopharmaceutical development, genetic skin disorder, orphan drug development
Industry2 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
Product category
Rare Disease Therapeutics
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Attruby (acoramidis)
Description

FDA-approved medicine for transthyretin amyloidosis (ATTRv)

bridgebio.com
+2 more records
Core offering1 text field

Phoenix Tissue Repair is a biotechnology company advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin disorder characterized by fragile skin and chronic blistering. The company is developing an investigational therapeutic candidate targeting this rare disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • $8 billion peak year sales potential
Product overview1 text field

The source data provided pertains to BridgeBio Pharma, Inc. (bridgebio.com), not Phoenix Tissue Repair. No product or service information about Phoenix Tissue Repair is present in the provided source content.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Abeona Therapeutics has historically developed EB-101 (prademagene zamikeracel), an autologous gene-corrected cell therapy for recessive dystrophic EB. It targets the same DEB patient population with a similar disease-modifying mechanism, making it a direct clinical-stage competitor to Phoenix Tissue Repair.

TypeBroad incumbent
Description

BridgeBio Pharma is the parent organization whose data fields appear in the provided dump and which houses multiple rare-disease subsidiaries including Phoenix Tissue Repair. It is a broader incumbent in rare genetic disease drug development with 3 FDA approvals, providing regulatory and capital infrastructure relevant to Phoenix Tissue Repair's program.

TypeDirect peer
Description

Castle Creek Biosciences develops FCX-007, a gene-modified autologous fibroblast therapy for dystrophic EB, and operates in the same DEB regulatory and clinical landscape as Phoenix Tissue Repair, with comparable modality and patient population focus.

TypeDirect peer
Description

Krystal Biotech developed and commercialized Vyjuvek (beremagene geperpavec), the first FDA-approved gene therapy for Dystrophic Epidermolysis Bullosa. It is the most directly comparable company to Phoenix Tissue Repair given overlapping indication, modality (genetic correction of skin fragility), and target patient population in DEB.

TypeDirect peer
Description

Fibrocell Science has historically developed autologous fibroblast-based therapies for rare skin and connective tissue disorders, including programs targeting dystrophic EB. Its therapeutic modality and target indications overlap directly with Phoenix Tissue Repair's regenerative skin approach.

TypeEmerging player
Description

Rznomics is developing RNA-based regenerative and gene-regulating therapies for rare diseases including programs targeting skin and connective-tissue disorders. Its emerging pipeline and rare-disease focus overlap with Phoenix Tissue Repair's single-indication, advanced-therapy profile.

TypeBroad incumbent
Description

Chiesi (which acquired Amryt Pharma) is a broad rare-disease pharmaceutical company with commercial infrastructure in dermatology and orphan disease distribution. It represents a plausible strategic acquirer or commercialization partner comparable to Phoenix Tissue Repair's likely commercial pathway.

8Astellas Gene Therapies
TypeBroad incumbent
Description

Astellas Gene Therapies (formerly Audentes) develops AAV-based gene therapies for rare genetic disorders and has active programs in neuromuscular and metabolic disease. As a large rare-disease incumbent with gene therapy infrastructure, it is comparable to the eventual scale-up pathway that Phoenix Tissue Repair may pursue under BridgeBio or independently.

TypeDirect peer
Description

Holostem Terapie Avanzate developed and commercializes Holoclar, an autologous limbal stem cell therapy for corneal regeneration, and has worked on epithelial stem cell therapies applicable to severe skin-fragility disorders. Its expertise in advanced-therapy medicinal products for skin and epithelial regeneration is directly comparable to Phoenix Tissue Repair's regenerative approach to DEB.

TypeEmerging player
Description

REGENXBIO develops AAV-based gene therapies for rare diseases including ophthalmology and metabolic disorders, with platform technology applicable to skin and connective tissue indications. Its modality overlap and rare-disease development focus make it a relevant emerging peer to Phoenix Tissue Repair.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phoenix Tissue Repair

Rare Disease Therapeuticsphoenixtissuerepair.com

Phoenix Tissue Repair is a private, early-stage Boston-based biotechnology company founded in 2017 that is developing a novel treatment for Dystrophic Epidermolysis Bullosa, a rare inherited skin disorder.

What Phoenix Tissue Repair does

Phoenix Tissue Repair is a private, early-stage biotechnology company founded in 2017 and headquartered in Boston, Massachusetts. According to its firmographic profile, the company is focused on advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare inherited skin disorder characterized by skin fragility and chronic blistering. The company operates with a small team of 1-10 employees, consistent with a research-stage biotech organization.

The bulk of the source content provided alongside this analysis pertains to BridgeBio Pharma, Inc., a separate late-stage pharmaceutical company with three FDA-approved products (Attruby/acoramidis and NULIBRY/fosdenopterin) and an investigational pipeline targeting multiple rare genetic diseases including ATTRv amyloidosis, LGMD2I/R9, ADH1, achondroplasia, hypochondroplasia, and Canavan disease. No product-level, financial, leadership, partnership, or strategic-move information specific to Phoenix Tissue Repair is disclosed in the input data beyond the firmographic profile. The relationship between Phoenix Tissue Repair and BridgeBio is not explicitly stated, and no underlying technology platform, business model, pricing, or revenue mechanics for Phoenix Tissue Repair can be characterized from the provided evidence.

Phoenix Tissue Repair firmographics

Firmographics
Name
Phoenix Tissue Repair
Legal name
BridgeBio Pharma, Inc.
Website
https://phoenixtissuerepair.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Phoenix Tissue Repair is a private, early-stage Boston-based biotechnology company founded in 2017 that is developing a novel treatment for Dystrophic Epidermolysis Bullosa, a rare inherited skin disorder.
Ownership category
akta.pro rank

Phoenix Tissue Repair industry classification

Industry
Product category
Rare Disease Therapeutics
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Rare disease therapeutics
  • Epidermolysis bullosa treatment
  • Biopharmaceutical development
  • Genetic skin disorder
  • Orphan drug development

Where Phoenix Tissue Repair is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Phoenix Tissue Repair business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Distribution channels2 records

Marketing channels6 records

Phoenix Tissue Repair product offering

Product offering

Core offering

Phoenix Tissue Repair is a biotechnology company advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin disorder characterized by fragile skin and chronic blistering. The company is developing an investigational therapeutic candidate targeting this rare disease.

Product overview

The source data provided pertains to BridgeBio Pharma, Inc. (bridgebio.com), not Phoenix Tissue Repair. No product or service information about Phoenix Tissue Repair is present in the provided source content.

Differentiator

Problem solved

Functional benefit

Brands

  • Attruby (acoramidis): FDA-approved medicine for transthyretin amyloidosis (ATTRv)
  • NULIBRY (fosdenopterin)
  • On Rare Podcast

Quantifiable outcome

  • $8 billion peak year sales potential

Companies that use Phoenix Tissue Repair

Customer profile

Segments1 record

Ideal customer profiles1 record

Phoenix Tissue Repair technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Phoenix Tissue Repair partnerships and signals

Strategic signal

Scale indicators3 records

Phoenix Tissue Repair competitors and assessment

Company assessment

Direct peers

  • Abeona Therapeutics: Abeona Therapeutics has historically developed EB-101 (prademagene zamikeracel), an autologous gene-corrected cell therapy for recessive dystrophic EB. It targets the same DEB patient population with a similar disease-modifying mechanism, making it a direct clinical-stage competitor to Phoenix Tissue Repair.
  • Castle Creek Biosciences: Castle Creek Biosciences develops FCX-007, a gene-modified autologous fibroblast therapy for dystrophic EB, and operates in the same DEB regulatory and clinical landscape as Phoenix Tissue Repair, with comparable modality and patient population focus.
  • Krystal Biotech: Krystal Biotech developed and commercialized Vyjuvek (beremagene geperpavec), the first FDA-approved gene therapy for Dystrophic Epidermolysis Bullosa. It is the most directly comparable company to Phoenix Tissue Repair given overlapping indication, modality (genetic correction of skin fragility), and target patient population in DEB.
  • Fibrocell Science: Fibrocell Science has historically developed autologous fibroblast-based therapies for rare skin and connective tissue disorders, including programs targeting dystrophic EB. Its therapeutic modality and target indications overlap directly with Phoenix Tissue Repair's regenerative skin approach.
  • Holostem Terapie Avanzate: Holostem Terapie Avanzate developed and commercializes Holoclar, an autologous limbal stem cell therapy for corneal regeneration, and has worked on epithelial stem cell therapies applicable to severe skin-fragility disorders. Its expertise in advanced-therapy medicinal products for skin and epithelial regeneration is directly comparable to Phoenix Tissue Repair's regenerative approach to DEB.

Broad incumbents

  • BridgeBio Pharma: BridgeBio Pharma is the parent organization whose data fields appear in the provided dump and which houses multiple rare-disease subsidiaries including Phoenix Tissue Repair. It is a broader incumbent in rare genetic disease drug development with 3 FDA approvals, providing regulatory and capital infrastructure relevant to Phoenix Tissue Repair's program.
  • Chiesi Farmaceutici: Chiesi (which acquired Amryt Pharma) is a broad rare-disease pharmaceutical company with commercial infrastructure in dermatology and orphan disease distribution. It represents a plausible strategic acquirer or commercialization partner comparable to Phoenix Tissue Repair's likely commercial pathway.
  • Astellas Gene Therapies: Astellas Gene Therapies (formerly Audentes) develops AAV-based gene therapies for rare genetic disorders and has active programs in neuromuscular and metabolic disease. As a large rare-disease incumbent with gene therapy infrastructure, it is comparable to the eventual scale-up pathway that Phoenix Tissue Repair may pursue under BridgeBio or independently.

Emerging players

  • Rznomics: Rznomics is developing RNA-based regenerative and gene-regulating therapies for rare diseases including programs targeting skin and connective-tissue disorders. Its emerging pipeline and rare-disease focus overlap with Phoenix Tissue Repair's single-indication, advanced-therapy profile.
  • REGENXBIO: REGENXBIO develops AAV-based gene therapies for rare diseases including ophthalmology and metabolic disorders, with platform technology applicable to skin and connective tissue indications. Its modality overlap and rare-disease development focus make it a relevant emerging peer to Phoenix Tissue Repair.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

Phoenix Tissue Repair social profiles

Digital presence

Phoenix Tissue Repair financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phoenix Tissue Repair leadership team

Management profile

Number of profiles

Phoenix Tissue Repair funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phoenix Tissue Repair M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phoenix Tissue Repair

What does Phoenix Tissue Repair do?

Phoenix Tissue Repair is a biotechnology company advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin disorder characterized by fragile skin and chronic blistering. The company is developing an investigational therapeutic candidate targeting this rare disease.

Is Phoenix Tissue Repair a public or private company?

Phoenix Tissue Repair is a private company. It is classified as unknown and is currently operating.

When was Phoenix Tissue Repair founded?

Phoenix Tissue Repair was founded in 2017. It employs 1 to 10 people.

Where is Phoenix Tissue Repair based?

Phoenix Tissue Repair is headquartered in Boston, United States, in the North America region.

Who are Phoenix Tissue Repair's main competitors?

Direct peers on record are Abeona Therapeutics, Castle Creek Biosciences, Krystal Biotech, Fibrocell Science and Holostem Terapie Avanzate. Broad incumbents are BridgeBio Pharma, Chiesi Farmaceutici and Astellas Gene Therapies. Emerging players are Rznomics and REGENXBIO.

Does Phoenix Tissue Repair have an API?

No public API is recorded for Phoenix Tissue Repair.

What industry is Phoenix Tissue Repair in?

Phoenix Tissue Repair's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBridgeBio Continues Comeback with Positive Epidermolysis Bullosa DataBridgeBio Pharma and Phoenix Tissue Repair announced positive Phase II data for PTR-01, a recombinant C7 protein treatment for recessive dystrophic epidermolysis bullosa. The 120-day trial showed 80% of target wounds achieved 50% or greater reduction in surface area, with 86% of recurrent and 75% of chronic wounds improving. The company will present the data at the SID Annual Meeting 2022 and has initiated a Phase II extension study.GlobeNewswireBridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis BullosaBridgeBio Pharma and affiliate Phoenix Tissue Repair announced positive Phase 2 trial results for PTR-01, a recombinant collagen 7 therapy for recessive dystrophic epidermolysis bullosa. Over 80% of target wounds showed at least 50% reduction in surface area, and all patients reported decreased pain. A Phase 2 extension study has been initiated.GlobeNewswireBridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEBBridgeBio Pharma and affiliate Phoenix Tissue Repair announced the first patient has been dosed in a Phase 2 study of BBP-589, an intravenously-administered recombinant collagen 7 protein replacement therapy for recessive dystrophic epidermolysis bullosa. The open-label study will enroll six patients over 18 weeks to assess wound healing and safety.GlobeNewswireBridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual MeetingPhoenix Tissue Repair will present interim data from a Phase 1/2 study of PTR-01, a recombinant collagen 7 therapy for recessive dystrophic epidermolysis bullosa, at the Society for Pediatric Dermatology's 45th Annual Meeting. The poster covers safety and tolerability in cohorts 1-3, with a pre-recorded presentation available online until December 31, 2020.PR NewswirePhoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Phoenix Tissue Repair announced the dosing of the first patient in its Phase 1/2 clinical trial for PTR-01, a protein replacement therapy designed to treat recessive dystrophic epidermolysis bullosa. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of the treatment in 14 patients over a 10-week period. This milestone marks a significant step in developing a disease-modifying therapy for this rare genetic disorder.